Literature DB >> 31102751

Underlying mechanisms of recombinant adeno-associated virus-mediated bicaudal C homolog 1 overexpression in the medial prefrontal cortex of mice with induced depressive-like behaviors.

Zhengchun Wang1, Dongsheng Zhou2, Shuting Li1, Yanhua Zhang1, Chuang Wang3.   

Abstract

Bicaudal C homolog 1 gene (BICC1) in the medial prefrontal cortex (mPFC) has been implicated in major depressive disorder (MDD); however, less is known about the mechanisms of BICC1-induced depression. The purpose of the present study was to investigate changes in depressive-like behaviors induced by recombinant adeno-associated virus (rAAV)-mediated overexpression of BICC1 in the mPFC of mice. A viral-mediated genetic approach was employed to explore the BICC1 overexpression-induced depressive-like behavioral and molecular changes in mice. For the first time, we found that BICC1 overexpression significantly induced depressive-like behaviors in mice. Further, the expression of disheveled-2 and the phosphorylation of Ser9 of glycogen synthase kinase 3β (GSK3β), mechanistic target of rapamycin (mTOR) and GluA1, GluA1, brain-derived neurotrophic factor (BDNF), and VGF were markedly down-regulated in BICC1 overexpression-treated animals. Our results demonstrate that the overexpression of BICC1 in the mPFC may induce depressive-like behaviors via GSK3β/mTOR signaling and GluA1 trafficking in the mPFC of mice, indicating that BICC1 may be a potential target for antidepressant treatment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bicaudal C homolog 1 gene (BICC1); Depression; GSK3β; GluA1; mTOR

Year:  2019        PMID: 31102751     DOI: 10.1016/j.brainresbull.2019.05.008

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  1 in total

Review 1.  Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.

Authors:  Ido Rippin; Hagit Eldar-Finkelman
Journal:  Cells       Date:  2021-01-29       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.